<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:31:28Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8751815" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8751815</identifier>
        <datestamp>2022-01-14</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah36846" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8751815</article-id>
              <article-id pub-id-type="pmcid">PMC8751815</article-id>
              <article-id pub-id-type="pmc-uid">8751815</article-id>
              <article-id pub-id-type="pmid">34713704</article-id>
              <article-id pub-id-type="pmid">34713704</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.121.021570</article-id>
              <article-id pub-id-type="publisher-id">JAH36846</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Resuscitation Science</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock</article-title>
                <alt-title alt-title-type="right-running-head">AMI Management and Outcomes in Cardiogenic Shock</alt-title>
                <alt-title alt-title-type="left-running-head">Jung et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah36846-cr-0001" contrib-type="author">
                  <name>
                    <surname>Jung</surname>
                    <given-names>Richard G.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8570-6736</contrib-id>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah36846-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="jah36846-note-0001" ref-type="author-notes">
                    <sup>
                      <sup>*</sup>
                    </sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0002" contrib-type="author">
                  <name>
                    <surname>Di Santo</surname>
                    <given-names>Pietro</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="jah36846-note-0001" ref-type="author-notes">
                    <sup>
                      <sup>*</sup>
                    </sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0003" contrib-type="author">
                  <name>
                    <surname>Mathew</surname>
                    <given-names>Rebecca</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="jah36846-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0004" contrib-type="author">
                  <name>
                    <surname>Abdel‐Razek</surname>
                    <given-names>Omar</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0005" contrib-type="author">
                  <name>
                    <surname>Parlow</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9294-4268</contrib-id>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0006" contrib-type="author">
                  <name>
                    <surname>Simard</surname>
                    <given-names>Trevor</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="jah36846-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0007" contrib-type="author">
                  <name>
                    <surname>Marbach</surname>
                    <given-names>Jeffrey A.</given-names>
                  </name>
                  <degrees>MBBS, MSc</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0008" contrib-type="author">
                  <name>
                    <surname>Gillmore</surname>
                    <given-names>Taylor</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="jah36846-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0009" contrib-type="author">
                  <name>
                    <surname>Mao</surname>
                    <given-names>Brennan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0010" contrib-type="author">
                  <name>
                    <surname>Bernick</surname>
                    <given-names>Jordan</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="jah36846-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0011" contrib-type="author">
                  <name>
                    <surname>Theriault‐Lauzier</surname>
                    <given-names>Pascal</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6931-2673</contrib-id>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0012" contrib-type="author">
                  <name>
                    <surname>Fu</surname>
                    <given-names>Angel</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0013" contrib-type="author">
                  <name>
                    <surname>Lau</surname>
                    <given-names>Lawrence</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0014" contrib-type="author">
                  <name>
                    <surname>Motazedian</surname>
                    <given-names>Pouya</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0015" contrib-type="author">
                  <name>
                    <surname>Russo</surname>
                    <given-names>Juan J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0016" contrib-type="author">
                  <name>
                    <surname>Labinaz</surname>
                    <given-names>Marino</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah36846-cr-0017" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Hibbert</surname>
                    <given-names>Benjamin</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0906-1363</contrib-id>
                  <xref rid="jah36846-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="jah36846-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="jah36846-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="jah36846-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <address>
                    <email>bhibbert@ottawaheart.ca</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah36846-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">CAPITAL Research Group</named-content>
                <named-content content-type="organisation-division">Division of Cardiology</named-content>
                <institution>University of Ottawa Heart Institute</institution>
                <city>Ottawa</city>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah36846-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Faculty of Medicine</named-content>
                <institution>University of Ottawa</institution>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah36846-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Cellular and Molecular Medicine</named-content>
                <institution>University of Ottawa</institution>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah36846-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">School of Epidemiology and Public Health</named-content>
                <institution>University of Ottawa</institution>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah36846-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiology</named-content>
                <institution>University of Ottawa Heart Institute</institution>
                <city>Ottawa</city>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah36846-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Division of Critical Care</named-content>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of Ottawa</institution>
                <named-content content-type="country-part">Ontario</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah36846-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Cardiovascular Medicine</named-content>
                <institution>Mayo Clinic</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">MN</named-content>
              </aff>
              <aff id="jah36846-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Division of Critical Care</named-content>
                <institution>Tufts Medical Center</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah36846-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Cardiovascular Research Methods Centre</named-content>
                <institution>University of Ottawa Heart Institute</institution>
                <city>Ottawa</city>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah36846-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <institution>University of Calgary</institution>
                <city>Alberta</city>
                <country country="CA">Canada</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Benjamin Hibbert, MD, PhD, University of Ottawa Heart Institute, 40 Ruskin Street, H‐4238, Ottawa, Ontario, Canada K1Y 4W7. E‐mail: <email>bhibbert@ottawaheart.ca</email>
<break/>
</corresp>
                <fn id="jah36846-note-0001">
                  <label>
                    <sup>*</sup>
                  </label>
                  <p>R. G. Jung and P. Di Santo contributed equally.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>29</day>
                <month>10</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>02</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <volume>10</volume>
              <issue seq="290">21</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v10.21</issue-id>
              <elocation-id>e021570</elocation-id>
              <history>
                <date date-type="received">
                  <day>09</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-10-e021570.pdf"/>
              <abstract id="jah36846-abs-0001">
                <sec id="jah36846-sec-0001">
                  <title>Background</title>
                  <p>The randomized DOREMI (Dobutamine Compared to Milrinone) clinical trial evaluated the efficacy and safety of milrinone and dobutamine in patients with cardiogenic shock. Whether the results remain consistent when stratified by acute myocardial infarction remains unknown. In this substudy, we sought to evaluate differences in clinical management and outcomes of acute myocardial infarction complicated by cardiogenic shock (AMICS) versus non‐AMICS.</p>
                </sec>
                <sec id="jah36846-sec-0002">
                  <title>Methods and Results</title>
                  <p>Patients in cardiogenic shock (n=192) were randomized 1:1 to dobutamine or milrinone. The primary composite end point in this subgroup analysis was all‐cause in‐hospital mortality, cardiac arrest, non‐fatal myocardial infarction, cerebrovascular accident, the need for mechanical circulatory support, or initiation of renal replacement therapy (RRT) at 30‐days. Outcomes were evaluated in patients with (n=65) and without (n=127) AMICS. The primary composite end point was significantly higher in AMICS versus non‐AMICS (hazard ratio [HR], 2.21; 95% CI, 1.47–3.30; <italic toggle="yes">P</italic>=0.0001). The primary end point was driven by increased rates of all‐cause mortality, mechanical circulatory support, and RRT. No differences in other secondary outcomes including cardiac arrest or cerebrovascular accident were observed. AMICS remained associated with the primary composite outcome, 30‐day mortality, and RRT after adjustment for age, sex, procedural contrast use, multivessel disease, and inotrope type.</p>
                </sec>
                <sec id="jah36846-sec-0003">
                  <title>Conclusions</title>
                  <p>AMI was associated with increased rates of adverse clinical outcomes in cardiogenic shock along with increased rates of mortality and initiation of mechanical circulatory support and RRT. Contrast administration during revascularization likely contributes to increased rates of RRT. Heterogeneity of outcomes in AMICS versus non‐AMICS highlights the need to study interventions in specific subgroups of cardiogenic shock.</p>
                </sec>
                <sec id="jah36846-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT03207165.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah36846-kwd-0001">acute myocardial infarction</kwd>
                <kwd id="jah36846-kwd-0002">cardiogenic shock</kwd>
                <kwd id="jah36846-kwd-0003">inotrope</kwd>
                <kwd id="jah36846-kwd-0004">mechanical circulatory support</kwd>
                <kwd id="jah36846-kwd-0005">renal replacement therapy</kwd>
                <kwd id="jah36846-kwd-0006">revascularization</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Myocardial Infarction</kwd>
                <kwd>Cardiopulmonary Resuscitation and Emergency Cardiac Care</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>Canadian Foundation of Innovation</funding-source>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>Vanier Canadian Institutes of Health Research Canada Graduate Scholarship</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="3"/>
                <page-count count="12"/>
                <word-count count="12958"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>November 2, 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.8 mode:remove_FC converted:02.11.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="jah36846-ntgp-0001">
                <fn id="jah36846-note-0002">
                  <p>Supplementary Material for this article is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.021570" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.021570</ext-link>
</p>
                </fn>
                <fn id="jah36846-note-0003">
                  <p>For Sources of Funding and Disclosures, see page 11.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah36846-body-0001">
            <def-list list-content="abbreviations" id="jah36846-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>AMICS</term>
                <def>
                  <p>acute myocardial infarction complicated by cardiogenic shock</p>
                </def>
              </def-item>
              <def-item>
                <term>CS</term>
                <def>
                  <p>cardiogenic shock</p>
                </def>
              </def-item>
              <def-item>
                <term>RRT</term>
                <def>
                  <p>renal replacement therapy</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah36846-blkfxd-0001">
                <sec id="jah36846-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah36846-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah36846-list-0001">
                        <list-item>
                          <p>In patients with cardiogenic shock treated with dobutamine or milrinone, those presenting with acute myocardial infarction had increased 30‐day all‐cause mortality and need for mechanical circulatory support.</p>
                        </list-item>
                        <list-item>
                          <p>Patients with acute myocardial infarction complicated by cardiogenic shock had an increased need for initiation of renal replacement therapy.</p>
                        </list-item>
                        <list-item>
                          <p>Despite concerns about the effect of dobutamine on heart rate and myocardial oxygen consumption, no differences in clinical outcomes were observed between inotropes.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah36846-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah36846-list-0002">
                        <list-item>
                          <p>There is heterogeneity with respect to the etiology of cardiogenic shock, and patients presenting because of acute myocardial infarction are at increased risk of adverse outcomes.</p>
                        </list-item>
                        <list-item>
                          <p>With increased incident renal replacement therapy in patients with cardiogenic shock presenting with myocardial infarction, renal protective strategies such as contrast administration minimization may be important considerations when managing these patients.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah36846-sec-0009">
              <p>Cardiogenic shock (CS) is defined by an inadequate cardiac output state resulting in end‐organ hypoperfusion.<xref rid="jah36846-bib-0001" ref-type="bibr"><sup>1</sup></xref> Acute myocardial infarction complicated by cardiogenic shock (AMICS) accounts for the majority of cardiogenic shock presentations.<xref rid="jah36846-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="jah36846-bib-0003" ref-type="bibr"><sup>3</sup></xref> Early revascularization has been shown to improve mortality in CS and remains a cornerstone of management.<xref rid="jah36846-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah36846-bib-0005" ref-type="bibr"><sup>5</sup></xref> More recently, revascularization of culprit‐only disease has become the standard in improving short‐term outcomes in this cohort.<xref rid="jah36846-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jah36846-bib-0007" ref-type="bibr"><sup>7</sup></xref> In contrast, CS may also present as a manifestation of chronic cardiac dysfunction and may have a different pathophysiology, response to therapy and prognosis.<xref rid="jah36846-bib-0002" ref-type="bibr"><sup>2</sup></xref>
</p>
              <p>Management of CS in the cardiac intensive care unit involves hemodynamic stabilization by vasopressors and inotropes.<xref rid="jah36846-bib-0002" ref-type="bibr"><sup>2</sup></xref> Four major randomized trials including the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK),<xref rid="jah36846-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah36846-bib-0005" ref-type="bibr"><sup>5</sup></xref> Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock (CULPRIT‐SHOCK),<xref rid="jah36846-bib-0007" ref-type="bibr"><sup>7</sup></xref> Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients With Cardiogenic Shock (IABP‐SHOCK II),<xref rid="jah36846-bib-0008" ref-type="bibr"><sup>8</sup></xref> and Intraaortic Balloon Pump in Cardiogenic Shock II<xref rid="jah36846-bib-0009" ref-type="bibr"><sup>9</sup></xref> have previously evaluated the effect of revascularization and supportive therapies exclusively in AMICS. Although revascularization options have been well‐studied in AMICS, the ubiquitous use of inotropes and vasopressors remains poorly studied.<xref rid="jah36846-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah36846-bib-0011" ref-type="bibr"><sup>11</sup></xref> Furthermore, comparative differences to non‐AMI etiologies of CS have not been evaluated. In CAPITAL‐DOREMI, patients with CS were randomized in a 1:1 ratio to receive either dobutamine or milrinone.<xref rid="jah36846-bib-0012" ref-type="bibr"><sup>12</sup></xref>
</p>
              <p>Given the lack of robust comparative outcome data in AMICS and non‐AMI etiologies of CS, we sought to evaluate differences between these subgroups of the DOREMI randomized trial.</p>
            </sec>
            <sec sec-type="methods" id="jah36846-sec-0010">
              <title>METHODS</title>
              <p>Ethics approval was received from the Ottawa Health Science Network Research Ethics Board and conducted according to the Helsinki Declaration. Written informed consent was obtained from all eligible participants or their substitute decision maker. The trial was registered in <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> (NCT03207165). All the data used for this analysis will be made available in the original CAPITAL‐DOREMI trial.<xref rid="jah36846-bib-0012" ref-type="bibr"><sup>12</sup></xref>
</p>
              <sec id="jah36846-sec-0011">
                <title>Study Design and Oversight</title>
                <p>The DOREMI (Dobutamine Compared to Milrinone) trial was a randomized, double‐blind clinical trial of dobutamine versus milrinone in CS. All eligible patients with CS requiring admission to the regional cardiac intensive care unit were randomly assigned (1:1) to dobutamine or milrinone as inotrope therapy.<xref rid="jah36846-bib-0012" ref-type="bibr"><sup>12</sup></xref> Inclusion criteria includes patients aged ≥18 years who met the Society for Cardiovascular Angiography and Interventions definitions of cardiogenic shock stages B through E<xref rid="jah36846-bib-0013" ref-type="bibr"><sup>13</sup></xref> and had met an indication for inotrope use: (1) clinical diagnosis of cardiogenic shock and systolic blood pressure &lt;90 mm Hg with signs of end‐organ dysfunction, (2) clinical evidence of systemic and/or pulmonary congestion despite use of vasodilators and/or diuretics, (3) acute coronary syndrome complicated by cardiogenic shock with hemodynamic reduction in cardiac index (&lt;1.8 L/min per m<sup>2</sup> and left ventricular end‐diastolic pressure &gt;18 mm Hg), (4) a clinically determined need to augment cardiac output in addition to ongoing vasopressor therapy, or (5) a treating team’s clinical assessment that inotropic therapy is required for developing cardiogenic shock without current evidence of hypoperfusion. For the exclusion criteria, patients were excluded if they had presented with out‐of‐hospital cardiac arrest, were pregnant, initiated an inotrope before randomization, treating physician’s gestalt that the patient was not eligible for the study, patient participating in another interventional trial, or if the patient or substitute decision maker was unable to provide written informed consent for the trial participation.<xref rid="jah36846-bib-0012" ref-type="bibr"><sup>12</sup></xref>
</p>
              </sec>
              <sec id="jah36846-sec-0012">
                <title>End Points</title>
                <p>Patients with both AMI and non‐AMI etiologies of CS were recruited in the DOREMI trial. Patients were categorized as AMICS with a confirmed diagnosis of ST‐segment‒elevation myocardial infarction (STEMI) or non‒ST‐segment‒elevation myocardial infarction (NSTEMI) by the Third Universal Definition of Myocardial Infarction.<xref rid="jah36846-bib-0014" ref-type="bibr"><sup>14</sup></xref> Non‐infarct related etiologies of CS included decompensated chronic heart failure, valvular heart disease, myocarditis, or low cardiac output state.</p>
                <p>The primary end point for this subgroup analysis was the composite of in‐hospital all‐cause mortality, resuscitated cardiac arrest, need for cardiac transplant or mechanical circulatory support, non‐fatal myocardial infarction, transient ischemic attack or stroke, or the initiation of renal replacement therapy (RRT) stratified by AMI and non‐AMI etiologies of CS censored at 30‐days. Secondary end points include components of the primary end point along with median number of days in the cardiac intensive care unit, days of hospital length‐of‐stay, total time on inotropes, and number of patients requiring non‐invasive or invasive mechanical ventilation following randomization. Furthermore, pre‐specified subgroup analyses to explore changes in hemodynamic and biochemical parameters such as heart rate, mean arterial pressure, hourly urine output, vasoactive‐inotropic score,<xref rid="jah36846-bib-0015" ref-type="bibr"><sup>15</sup></xref> serum creatinine, sodium, potassium, troponin, and creatine kinase levels were performed.</p>
              </sec>
              <sec id="jah36846-sec-0013">
                <title>Statistical Analysis</title>
                <p>The subgroup analysis according to AMICS was conducted as a post‐hoc analysis. All analyses were performed according to the intention‐to‐treat principle which included all patients according to the group to which they were randomized. Data were summarized as descriptive statistics and presented as proportions (n, %) or mean±SD or median (quartiles, Q1 and Q3). Differences in continuous variables were compared using the Student <italic toggle="yes">t‐</italic>test or Mann‐Whitney <italic toggle="yes">U</italic> test and differences in categorical variables were compared by Chi‐Square Test or Fisher Exact Test, as appropriate. Event rates were based on Kaplan‒Meier estimates in the time‐to‐first‐event analysis and compared by log‐rank tests and hazard ratios were calculated by Cox proportional hazards model and presented as hazard ratios (HR) and 95% CI and adjusted for age, sex, volume of contrast used, multivessel disease, and inotrope type. For variables measured more than once throughout the study, a repeated measure mixed model for continuous variables was used to test the statistical significance of the association between AMI and non‐AMI etiologies of CS and outcome. A post‐hoc restricted cubic spline analysis (4 knots) was performed stratifying contrast volume to examine the association between acute kidney injury or renal replacement therapy with contrast volume. All analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA) and all figures were generated using GraphPad Prism v8 (GraphPad Software, La Jolla, CA, USA).</p>
              </sec>
              <sec sec-type="data-availability" id="jah36846-sec-0014">
                <title>Availability of Data and Materials</title>
                <p>The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah36846-sec-0015">
              <title>RESULTS</title>
              <sec id="jah36846-sec-0016">
                <title>Baseline and Procedural Characteristics</title>
                <p>From September 1, 2017 to May 17, 2020, a total of 319 patients were screened for eligibility in this study. Overall, 192 patients enrolled in the trial and were randomized in a 1:1 fashion to dobutamine or milrinone. In the milrinone group, 31 (32.3%) patients presented with AMICS and 65 (67.7%) presented with non‐AMICS. In the dobutamine group, 34 (35.4%) patients presented with AMICS and 62 (64.6%) presented with non‐AMICS (Figure <xref rid="jah36846-fig-0001" ref-type="fig">1</xref>). Amongst the 65 patients presenting with AMICS, 47 (72.3%) patients presented with STEMI and 18 (27.7%) presented with NSTEMI.</p>
                <fig position="float" fig-type="Figure" id="jah36846-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <title>Study flow diagram.</title>
                    <p>Flow diagram of patient enrollment, showing ineligible patients at screening, randomization 1:1 to inotrope type, and divided by acute myocardial infarction status. AMICS indicates acute myocardial infarction complicated by cardiogenic shock; and CICU, critical intensive care unit.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e021570-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>Baseline characteristics were similar between AMI and non‐AMI etiologies of CS (Table <xref rid="jah36846-tbl-0001" ref-type="table">1</xref>). Mean age of patients was 72.1±11.5 years versus 69.6±13.2 years and 21 (32.3%) and 49 (38.6%) were women for AMICS and non‐AMICS, respectively. Patients were evenly distributed in Society for Cardiovascular Angiography and Interventions definition of CS and inotrope randomization. Presence of comorbidities including hypertension, diabetes, dyslipidemia, active smoker, prior coronary artery bypass grafting, myocardial infarction, percutaneous coronary intervention and prior stroke or transient ischemic attack remained similar in both groups. AMICS and non‐AMICS have differences in medications received 24 hours before randomization including aspirin, P2Y<sub>12</sub> inhibitor, warfarin, beta‐blocker, diuretic use, and amiodarone administration.</p>
                <table-wrap position="float" id="jah36846-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Non‐AMI etiology of cardiogenic shock (n=127)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">AMI complicated by cardiogenic shock (n=65)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y, mean±SD</td>
                        <td align="left" rowspan="1" colspan="1">69.6±13.2</td>
                        <td align="left" rowspan="1" colspan="1">72.1±11.5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Women, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">49 (38.6)</td>
                        <td align="left" rowspan="1" colspan="1">21 (32.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Body mass index, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">26.3 (23.3–31.5)</td>
                        <td align="left" rowspan="1" colspan="1">26.1 (22.9–30.7)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Inotrope, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Milrinone</td>
                        <td align="left" rowspan="1" colspan="1">65 (51.2)</td>
                        <td align="left" rowspan="1" colspan="1">31 (47.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median dose (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">0.13 (0.00–0.13)</td>
                        <td align="left" rowspan="1" colspan="1">0.00 (0.00–0.13)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dobutamine</td>
                        <td align="left" rowspan="1" colspan="1">62 (48.8)</td>
                        <td align="left" rowspan="1" colspan="1">34 (52.3)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Median dose (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">0.00 (0.00–2.50)</td>
                        <td align="left" rowspan="1" colspan="1">2.50 (0.00–2.50)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Race, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td>
                        <td align="left" rowspan="1" colspan="1">112 (88.2)</td>
                        <td align="left" rowspan="1" colspan="1">53 (81.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other races</td>
                        <td align="left" rowspan="1" colspan="1">15 (11.8)</td>
                        <td align="left" rowspan="1" colspan="1">12 (18.5)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Left ventricular function, n. (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left ventricular ejection fraction, median (IQR)—%</td>
                        <td align="left" rowspan="1" colspan="1">25.0 (18.0–36.0)</td>
                        <td align="left" rowspan="1" colspan="1">27.0 (20.0–45.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" colspan="3" rowspan="1">Etiology of ventricular dysfunction</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ischemic</td>
                        <td align="left" rowspan="1" colspan="1">64 (50.8)</td>
                        <td align="left" rowspan="1" colspan="1">64 (98.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Non‐ischemic</td>
                        <td align="left" rowspan="1" colspan="1">62 (49.2)</td>
                        <td align="left" rowspan="1" colspan="1">1 (1.5)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Comorbidities, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous myocardial infarction</td>
                        <td align="left" rowspan="1" colspan="1">45 (35.4)</td>
                        <td align="left" rowspan="1" colspan="1">23 (35.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous percutaneous coronary intervention</td>
                        <td align="left" rowspan="1" colspan="1">30 (23.6)</td>
                        <td align="left" rowspan="1" colspan="1">19 (29.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous coronary artery bypass grafting</td>
                        <td align="left" rowspan="1" colspan="1">27 (21.3)</td>
                        <td align="left" rowspan="1" colspan="1">12 (18.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Previous stroke/transient ischemic attack</td>
                        <td align="left" rowspan="1" colspan="1">18 (14.2)</td>
                        <td align="left" rowspan="1" colspan="1">10 (15.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Atrial fibrillation</td>
                        <td align="left" rowspan="1" colspan="1">82 (64.6)</td>
                        <td align="left" rowspan="1" colspan="1">13 (20.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic kidney disease</td>
                        <td align="left" rowspan="1" colspan="1">35 (27.6)</td>
                        <td align="left" rowspan="1" colspan="1">15 (23.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic liver disease</td>
                        <td align="left" rowspan="1" colspan="1">10 (7.9)</td>
                        <td align="left" rowspan="1" colspan="1">3 (4.6)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td>
                        <td align="left" rowspan="1" colspan="1">15 (11.8)</td>
                        <td align="left" rowspan="1" colspan="1">10 (15.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">84 (66.1)</td>
                        <td align="left" rowspan="1" colspan="1">42 (64.6)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes</td>
                        <td align="left" rowspan="1" colspan="1">59 (46.5)</td>
                        <td align="left" rowspan="1" colspan="1">23 (35.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidemia</td>
                        <td align="left" rowspan="1" colspan="1">65 (51.2)</td>
                        <td align="left" rowspan="1" colspan="1">37 (36.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Active smoker</td>
                        <td align="left" rowspan="1" colspan="1">19 (15.0)</td>
                        <td align="left" rowspan="1" colspan="1">9 (13.9)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Medications received in 24 h before randomization, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td>
                        <td align="left" rowspan="1" colspan="1">65 (51.2)</td>
                        <td align="left" rowspan="1" colspan="1">62 (95.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">P2Y12 inhibitor</td>
                        <td align="left" rowspan="1" colspan="1">37 (27.4)</td>
                        <td align="left" rowspan="1" colspan="1">62 (95.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Warfarin</td>
                        <td align="left" rowspan="1" colspan="1">19 (15.0)</td>
                        <td align="left" rowspan="1" colspan="1">2 (3.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Direct oral anticoagulant</td>
                        <td align="left" rowspan="1" colspan="1">34 (25.2)</td>
                        <td align="left" rowspan="1" colspan="1">7 (10.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td>
                        <td align="left" rowspan="1" colspan="1">78 (61.4)</td>
                        <td align="left" rowspan="1" colspan="1">48 (73.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Beta‐blocker</td>
                        <td align="left" rowspan="1" colspan="1">71 (55.9)</td>
                        <td align="left" rowspan="1" colspan="1">22 (33.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angiotensin‐converting enzyme inhibitor, angiotensin‐II receptor blocker, or angiotensin receptor neprolysin inhibitor</td>
                        <td align="left" rowspan="1" colspan="1">62 (45.9)</td>
                        <td align="left" rowspan="1" colspan="1">23 (35.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mineralocorticoid receptor antagonist</td>
                        <td align="left" rowspan="1" colspan="1">25 (19.7)</td>
                        <td align="left" rowspan="1" colspan="1">4 (6.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Nitrates/hydralazine</td>
                        <td align="left" rowspan="1" colspan="1">19 (14.1)</td>
                        <td align="left" rowspan="1" colspan="1">7 (10.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diuretic</td>
                        <td align="left" rowspan="1" colspan="1">110 (86.6)</td>
                        <td align="left" rowspan="1" colspan="1">41 (63.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Digoxin</td>
                        <td align="left" rowspan="1" colspan="1">12 (9.5)</td>
                        <td align="left" rowspan="1" colspan="1">2 (3.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amiodarone</td>
                        <td align="left" rowspan="1" colspan="1">55 (40.7)</td>
                        <td align="left" rowspan="1" colspan="1">12 (18.5)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Society for cardiovascular angiography and interventions cardiogenic shock class, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Class B</td>
                        <td align="left" rowspan="1" colspan="1">7 (5.5)</td>
                        <td align="left" rowspan="1" colspan="1">4 (6.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Class C</td>
                        <td align="left" rowspan="1" colspan="1">106 (83.5)</td>
                        <td align="left" rowspan="1" colspan="1">49 (75.4)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Class D</td>
                        <td align="left" rowspan="1" colspan="1">11 (8.7)</td>
                        <td align="left" rowspan="1" colspan="1">11 (16.9)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Class E</td>
                        <td align="left" rowspan="1" colspan="1">3 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">1 (1.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Vasopressor, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">51 (40.2)</td>
                        <td align="left" rowspan="1" colspan="1">38 (58.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Norepinephrine</td>
                        <td align="left" rowspan="1" colspan="1">51 (40.2)</td>
                        <td align="left" rowspan="1" colspan="1">38 (58.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Phenylephrine</td>
                        <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                        <td align="left" rowspan="1" colspan="1">1 (1.5)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vasopressin</td>
                        <td align="left" rowspan="1" colspan="1">5 (3.9)</td>
                        <td align="left" rowspan="1" colspan="1">5 (7.7)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Epinephrine</td>
                        <td align="left" rowspan="1" colspan="1">3 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">2 (3.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dopamine</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">3 (4.6)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Hemodynamic parameters, median (IQR)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart rate</td>
                        <td align="left" rowspan="1" colspan="1">94 (75–108)</td>
                        <td align="left" rowspan="1" colspan="1">88 (72–99)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic blood pressure</td>
                        <td align="left" rowspan="1" colspan="1">108 (93–119)</td>
                        <td align="left" rowspan="1" colspan="1">108 (98–118)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic blood pressure</td>
                        <td align="left" rowspan="1" colspan="1">62 (50–72)</td>
                        <td align="left" rowspan="1" colspan="1">59 (54–70)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean arterial pressure</td>
                        <td align="left" rowspan="1" colspan="1">76 (68–84)</td>
                        <td align="left" rowspan="1" colspan="1">75 (67–84)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Intra‐aortic balloon pump, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">8 (12.3)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="3" rowspan="1">Ventilation, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non‐invasive</td>
                        <td align="left" rowspan="1" colspan="1">13 (10.2)</td>
                        <td align="left" rowspan="1" colspan="1">4 (6.2)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Invasive</td>
                        <td align="left" rowspan="1" colspan="1">16 (12.6)</td>
                        <td align="left" rowspan="1" colspan="1">24 (36.9)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah36846-ntgp-0002">
                    <fn id="jah36846-note-0004">
                      <p>AMI indicates acute myocardial infarction; and IQR, interquartile range.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <p>Patients presenting with AMICS were more likely to have multivessel coronary disease (60.0% versus 8.9%; <italic toggle="yes">P</italic>&lt;0.0001), have contrast exposure (100.0% versus 38.5%; <italic toggle="yes">P</italic>&lt;0.0001), undergo revascularization (92.3% versus 9.6%; <italic toggle="yes">P</italic>&lt;0.0001), and longer time to revascularization (10.1 [5.7–21.4] hours versus 4.0 [2.0–7.2] hours; <italic toggle="yes">P</italic>=0.02; Table <xref rid="jah36846-tbl-0002" ref-type="table">2</xref>). Among non‐AMICS, patients who underwent coronary angiography were more likely to have received invasive ventilation (29.0% versus 7.3%; <italic toggle="yes">P</italic>=0.004; Table <xref rid="jah36846-sup-0001" ref-type="supplementary-material">S1</xref>). We saw no difference in baseline chronic kidney disease (23.1% versus 27.6%; <italic toggle="yes">P</italic>=0.50) in AMICS versus non‐AMI etiologies of CS.</p>
                <table-wrap position="float" id="jah36846-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Biochemical and Procedural Characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Non‐AMI etiology of cardiogenic shock (n=127)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">AMI complicated by cardiogenic shock (n=65)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline eGFR—mL/min per 1.73 m<sup>2</sup>, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">63.5 (43.0–94.5)</td>
                        <td align="left" rowspan="1" colspan="1">63.0 (36.0–89.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.46</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline chronic kidney disease, n (%) (n=172)</td>
                        <td align="left" rowspan="1" colspan="1">35 (27.6)</td>
                        <td align="left" rowspan="1" colspan="1">15 (23.1)</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Catheterization procedural characteristics</td>
                        <td align="left" rowspan="1" colspan="1">(n=52)</td>
                        <td align="left" rowspan="1" colspan="1">(n=65)</td>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multivessel disease (≥1)</td>
                        <td align="left" rowspan="1" colspan="1">12 (8.9)</td>
                        <td align="left" rowspan="1" colspan="1">39 (60.0)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Contrast volume (mL), median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">0.0 (0.0–65.0)</td>
                        <td align="left" rowspan="1" colspan="1">213.0 (147.0–279.0)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Contrast used, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">52 (38.5)</td>
                        <td align="left" rowspan="1" colspan="1">65 (100.0)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coronary intervention, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">13 (9.6)</td>
                        <td align="left" rowspan="1" colspan="1">60 (92.3)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">GP IIb/IIIa use, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                        <td align="left" rowspan="1" colspan="1">1 (1.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.46</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median time to revascularization—h, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">4.0 (2.0–7.2)</td>
                        <td align="left" rowspan="1" colspan="1">10.1 (5.7–21.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Laboratory values at initiation of inotropes</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin, median (IQR), g/L</td>
                        <td align="left" rowspan="1" colspan="1">118.0 (100.0–135.0)</td>
                        <td align="left" rowspan="1" colspan="1">116.0 (100.0–134.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.90</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Platelet, median (IQR), g/L</td>
                        <td align="left" rowspan="1" colspan="1">212.5 (170.0–282.0)</td>
                        <td align="left" rowspan="1" colspan="1">271.0 (226.0–315.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.0002</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lactate, median (IQR), mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">3.0 (2.1–4.5)</td>
                        <td align="left" rowspan="1" colspan="1">2.8 (1.7–4.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.43</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Serum creatinine, median (IQR), µmol/L</td>
                        <td align="left" rowspan="1" colspan="1">152.5 (122.0–226.0)</td>
                        <td align="left" rowspan="1" colspan="1">143.0 (112.0–201.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.14</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Blood urea nitrogen, median (IQR), mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">15.9 (10.4–24.0)</td>
                        <td align="left" rowspan="1" colspan="1">12.0 (9.1–16.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.006</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Serum sodium, median (IQR), mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">135.0 (132.0–138.0)</td>
                        <td align="left" rowspan="1" colspan="1">137.0 (133.0–139.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.06</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Serum potassium, median (IQR), mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">4.5 (4.0–4.9)</td>
                        <td align="left" rowspan="1" colspan="1">4.2 (3.8–4.7)</td>
                        <td align="left" rowspan="1" colspan="1">0.04</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Serum bicarbonate, median (IQR), mmol/L</td>
                        <td align="left" rowspan="1" colspan="1">22.0 (19.0–26.0)</td>
                        <td align="left" rowspan="1" colspan="1">20.0 (17.0–23.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Blood pH, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">7.37 (7.30–7.43)</td>
                        <td align="left" rowspan="1" colspan="1">7.36 (7.27–7.42)</td>
                        <td align="left" rowspan="1" colspan="1">0.36</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Serum troponin, median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">125.5 (43.5–728.0)</td>
                        <td align="left" rowspan="1" colspan="1">29 540.0 (5578.0–40 000.0)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah36846-ntgp-0003">
                    <fn id="jah36846-note-0005">
                      <p>Comparisons were conducted by chi‐squares test or Mann‐Whitney <italic toggle="yes">U</italic> test. AMI indicates acute myocardial infarction; eGFR, estimated glomerular filtration rate; and IQR, interquartile range.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="jah36846-sec-0017">
                <title>Clinical Outcomes</title>
                <p>As demonstrated in Table <xref rid="jah36846-tbl-0003" ref-type="table">3</xref> and Figure <xref rid="jah36846-fig-0002" ref-type="fig">2</xref>, AMICS was associated with increased incidence of the unadjusted primary composite end point at 30‐days (HR, 2.21; 95% CI, 1.47–3.30; <italic toggle="yes">P</italic>=0.0001; Figure <xref rid="jah36846-fig-0002" ref-type="fig">2A</xref>). However, no differences in 30‐day cardiac arrest (HR, 1.68; 95% CI, 0.63–4.51; <italic toggle="yes">P</italic>=0.30; Figure <xref rid="jah36846-fig-0002" ref-type="fig">2B</xref>) nor cerebrovascular accident (HR, 4.63; 95% CI, 0.42–51.15; <italic toggle="yes">P</italic>=0.17; Figure <xref rid="jah36846-fig-0002" ref-type="fig">2C</xref>) was observed between the 2 groups. AMICS was associated with increased rate of 30‐day mortality (HR, 1.62; 95% CI, 1.01–2.59; <italic toggle="yes">P</italic>=0.04; Figure <xref rid="jah36846-fig-0002" ref-type="fig">2D</xref>), mechanical circulatory support (HR, 2.67; 95% CI, 1.21–5.88; <italic toggle="yes">P</italic>=0.01; Figure <xref rid="jah36846-fig-0002" ref-type="fig">2E</xref>) and RRT (HR, 3.14; 95% CI, 1.60–6.14; <italic toggle="yes">P</italic>=0.001; Figure <xref rid="jah36846-fig-0002" ref-type="fig">2F</xref>). The primary composite end point, 30‐day mortality, and initiation of RRT remained associated with AMICS after adjustment of age, sex, contrast use, multivessel disease, and inotrope type (Table <xref rid="jah36846-tbl-0003" ref-type="table">3</xref>). When stratified by inotrope type in AMICS, no differences in primary composite end point were observed with dobutamine and milrinone (Figure <xref rid="jah36846-sup-0001" ref-type="supplementary-material">S1</xref>).</p>
                <table-wrap position="float" id="jah36846-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Primary and Secondary Outcomes</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">Non‐AMI etiology of cardiogenic shock (n=127)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">AMI complicated by cardiogenic shock (n=65)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Unadjusted hazard ratio (95% CI)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Adjusted hazard ratio (95% CI)<xref rid="jah36846-note-0007" ref-type="table-fn">*</xref>
</th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Primary outcome, n (%)</td>
                        <td align="left" rowspan="1" colspan="1">54 (42.5)</td>
                        <td align="left" rowspan="1" colspan="1">43 (66.2)</td>
                        <td align="left" rowspan="1" colspan="1">2.21 (1.47–3.30)</td>
                        <td align="left" rowspan="1" colspan="1">0.0001</td>
                        <td align="left" rowspan="1" colspan="1">2.62 (1.38–4.95)</td>
                        <td align="left" rowspan="1" colspan="1">0.003</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="7" rowspan="1">Secondary outcomes, n (%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">All‐cause mortality</td>
                        <td align="left" rowspan="1" colspan="1">42 (33.1)</td>
                        <td align="left" rowspan="1" colspan="1">30 (46.2)</td>
                        <td align="left" rowspan="1" colspan="1">1.62 (1.01–2.59)</td>
                        <td align="left" rowspan="1" colspan="1">0.04</td>
                        <td align="left" rowspan="1" colspan="1">3.11 (1.43–6.76)</td>
                        <td align="left" rowspan="1" colspan="1">0.004</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Resuscitated cardiac arrest</td>
                        <td align="left" rowspan="1" colspan="1">9 (7.1)</td>
                        <td align="left" rowspan="1" colspan="1">7 (10.8)</td>
                        <td align="left" rowspan="1" colspan="1">1.68 (0.63–4.51)</td>
                        <td align="left" rowspan="1" colspan="1">0.30</td>
                        <td align="left" rowspan="1" colspan="1">2.25 (0.45–11.24)</td>
                        <td align="left" rowspan="1" colspan="1">0.32</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Need for mechanical circulatory support or cardiac transplant</td>
                        <td align="left" rowspan="1" colspan="1">12 (9.5)</td>
                        <td align="left" rowspan="1" colspan="1">13 (20.0)</td>
                        <td align="left" rowspan="1" colspan="1">2.67 (1.21–5.88)</td>
                        <td align="left" rowspan="1" colspan="1">0.01</td>
                        <td align="left" rowspan="1" colspan="1">1.93 (0.51–7.29)</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Intra‐aortic balloon pump</td>
                        <td align="left" rowspan="1" colspan="1">6 (4.7)</td>
                        <td align="left" rowspan="1" colspan="1">12 (18.5)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Impella</td>
                        <td align="left" rowspan="1" colspan="1">3 (2.4)</td>
                        <td align="left" rowspan="1" colspan="1">1 (1.5)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Extracorporeal membrane oxygenation</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Left ventricular assist device</td>
                        <td align="left" rowspan="1" colspan="1">2 (1.6)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non‐fatal myocardial infarction</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">0 (0.0)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Transient ischemic attack or stroke</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.8)</td>
                        <td align="left" rowspan="1" colspan="1">2 (3.1)</td>
                        <td align="left" rowspan="1" colspan="1">4.63 (0.42–51.15)</td>
                        <td align="left" rowspan="1" colspan="1">0.21</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Initiation of renal replacement therapy</td>
                        <td align="left" rowspan="1" colspan="1">15 (11.8)</td>
                        <td align="left" rowspan="1" colspan="1">20 (30.8)</td>
                        <td align="left" rowspan="1" colspan="1">3.14 (1.60–6.14)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                        <td align="left" rowspan="1" colspan="1">4.68 (1.69–12.96)</td>
                        <td align="left" rowspan="1" colspan="1">0.003</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median number of days of cardiac intensive care unit length of stay</td>
                        <td align="left" rowspan="1" colspan="1">7.0 (4.0–8.0)</td>
                        <td align="left" rowspan="1" colspan="1">7.0 (6.0–9.0)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">0.09</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median hospital length of stay (d)</td>
                        <td align="left" rowspan="1" colspan="1">17.0 (9.0–30.0)</td>
                        <td align="left" rowspan="1" colspan="1">11.0 (4.0–21.0)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">0.007</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median total time on inotropes (h)</td>
                        <td align="left" rowspan="1" colspan="1">63.0 (28.0–168.0)</td>
                        <td align="left" rowspan="1" colspan="1">77.0 (32.0–168.0)</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">0.80</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">No. of patients requiring non‐invasive or invasive mechanical ventilation after randomization only</td>
                        <td align="left" rowspan="1" colspan="1">9 (7.1)</td>
                        <td align="left" rowspan="1" colspan="1">4 (6.2)</td>
                        <td align="left" rowspan="1" colspan="1">0.95 (0.65–1.39)</td>
                        <td align="left" rowspan="1" colspan="1">0.81</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                        <td align="left" rowspan="1" colspan="1">…</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah36846-ntgp-0004">
                    <fn id="jah36846-note-0006">
                      <p>Primary composite outcome: composite of all‐cause in‐hospital mortality, resuscitated cardiac arrest, non‐fatal myocardial infarction, transient ischemic attack, or stroke, need for mechanical circulatory support or cardiac transplant, or initiation of renal replacement therapy. Values are reported as n (%) or median (interquartile range). All analyses performed using the intention‐to‐treat principle. <italic toggle="yes">P</italic>&lt;0.05 is considered statistically significant.</p>
                    </fn>
                    <fn id="jah36846-note-0007">
                      <label>*</label>
                      <p>Adjusted for age, sex, contrast use, multivessel disease, and inotrope type.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <fig position="float" fig-type="Figure" id="jah36846-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <title>Kaplan‒Meier estimates in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) vs non‐AMICS by primary and secondary end points.</title>
                    <p><bold>A</bold>, AMICS was associated with increased rates of primary composite end point (hazard ratio [HR], 2.21; 95% CI, 1.47–3.30; <italic toggle="yes">P</italic>=0.0001). <bold>B</bold>, No differences in rates of cardiac arrest was observed with AMICS vs non‐AMICS (HR, 1.68; 95% CI, 0.63–4.51; <italic toggle="yes">P</italic>=0.30). <bold>C</bold>, No differences in rates of CVA was observed with AMICS vs non‐AMICS (HR, 4.63; 95% CI, 0.42–51.15; <italic toggle="yes">P</italic>=0.21). <bold>D</bold>, AMICS was associated with increased rates of 30‐day all‐cause mortality (HR, 1.62; 95% CI, 1.01–2.59; <italic toggle="yes">P</italic>=0.04). <bold>E</bold>, AMICS was associated with increased rates of need for mechanical circulatory support or cardiac transplant (HR, 2.67; 95% CI, 1.21–5.88; <italic toggle="yes">P</italic>=0.01). <bold>F</bold>, AMICS was associated with increased initiation of renal replacement therapy (HR, 3.14; 95% CI, 1.60–6.14; <italic toggle="yes">P</italic>=0.001). Comparisons were made by log‐rank test and hazard ratios were evaluated using the Cox proportional hazards model. <italic toggle="yes">P</italic>&lt;0.05 is considered statistically significant. AMICS indicates acute myocardial infarction complicated by cardiogenic shock; CVA, cerebrovascular accident; and MCS, mechanical circulatory support.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e021570-g003" position="anchor" id="jats-graphic-3"/>
                </fig>
                <p>Furthermore, no differences in the median number of days in the cardiac intensive care unit (7.0 [6.0–9.0] days versus 7.0 [4.0–8.0] days; <italic toggle="yes">P</italic>=0.09) or total time on inotropes (77.0 [32.0–168.0] hours versus 63.0 [28.0–168.0] hours; <italic toggle="yes">P</italic>=0.80) was observed between AMICS and non‐AMI etiologies of CS, respectively (Table <xref rid="jah36846-tbl-0002" ref-type="table">2</xref>). Median hospital length‐of‐stay was shorter (11.0 [4.0–21.0] days versus 17.0 [9.0–30.0] days; <italic toggle="yes">P</italic>=0.01). Elevated level of troponin and creatine kinase was observed in AMICS whereas no differences were seen between AMICS and non‐AMI etiologies of CS in hemodynamic parameters including heart rate, mean arterial pressure, vasoactive‐inotrope score, or lactate levels (Figure <xref rid="jah36846-fig-0003" ref-type="fig">3A through 3F</xref>).</p>
                <fig position="float" fig-type="Figure" id="jah36846-fig-0003">
                  <label>Figure 3</label>
                  <caption>
                    <title>Changes in key hemodynamic and biochemical parameters from baseline to 120 hours.</title>
                    <p><bold>A</bold>, Troponin T (ng/mL; <italic toggle="yes">P</italic>&lt;0.0001). <bold>B</bold>, Creatine kinase (IU/L; <italic toggle="yes">P</italic>&lt;0.0001). <bold>C</bold>, Heart rate (beats per minute [bpm]; <italic toggle="yes">P</italic>=0.66). <bold>D</bold>, Mean arterial pressure (mm Hg; <italic toggle="yes">P</italic>=0.29). <bold>E</bold>, Vasoactive‐inotropic score (<italic toggle="yes">P</italic>=0.04). <bold>F</bold>, Lactate (mmol/L; <italic toggle="yes">P</italic>=0.30). A repeated measure mixed model was utilized to evaluate differences in the continuous variables between the 2 groups. All panels reveal mean±95% CIs with blue representing non acute myocardial infarction complicated by cardiogenic shock and red representing acute myocardial infarction complicated by cardiogenic shock. AMICS indicates acute myocardial infarction complicated by cardiogenic shock</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e021570-g004" position="anchor" id="jats-graphic-5"/>
                </fig>
              </sec>
              <sec id="jah36846-sec-0018">
                <title>Renal End Points</title>
                <p>When stratified by AMICS versus non‐AMI etiologies of CS, renal function was impaired with a significant decrease in mean urine output levels in AMICS (<italic toggle="yes">P</italic>=0.0003; Figure <xref rid="jah36846-fig-0004" ref-type="fig">4A</xref>) with no significant changes to serum creatinine or potassium levels (Figure <xref rid="jah36846-fig-0004" ref-type="fig">4B and 4C</xref>). Procedural contrast volume was higher in AMICS compared with non‐AMI etiologies of CS (213.0 [147.0–279.0] mL versus 0.0 [0.0–65.0] mL; <italic toggle="yes">P</italic>&lt;0.0001; Figure <xref rid="jah36846-fig-0004" ref-type="fig">4D</xref>). A restricted cubic spline analysis reveals a non‐linear relationship between contrast volume used and acute kidney injury (Figure <xref rid="jah36846-sup-0001" ref-type="supplementary-material">S2</xref>). Moreover, the restricted cubic spline analysis shows a non‐linear relationship between contrast volume and renal replacement therapy with an increased risk of renal replacement therapy with contrast volumes ≥225 mL (odds ratio, 1.36; 95% CI, 1.04–1.83; Figure <xref rid="jah36846-sup-0001" ref-type="supplementary-material">S3</xref>).</p>
                <fig position="float" fig-type="Figure" id="jah36846-fig-0004">
                  <label>Figure 4</label>
                  <caption>
                    <title>Renal outcomes.</title>
                    <p><bold>A</bold>, Changes in urine output (mL/h) from baseline to 120 hours (<italic toggle="yes">P</italic>=0.0003). <bold>B</bold>, Changes in creatinine (µmol/L) from baseline to 120 hours (<italic toggle="yes">P</italic>=0.39). <bold>C</bold>, Changes in serum potassium levels (mmol/L) from baseline to 120 hours (<italic toggle="yes">P</italic>=0.23). <bold>D</bold>, Contrast volume was elevated in acute myocardial infarction complicated by cardiogenic shock (213.0 [147.0–279.0] mL vs 0.0 [0.0–65.0] mL; <italic toggle="yes">P</italic>&lt;0.0001). A repeated measure mixed model was used to evaluate differences in the continuous variables between the 2 groups. All panels reveal mean±95% CIs with blue representing nonacute myocardial infarction complicated by cardiogenic shock and red representing patients with acute myocardial infarction complicated by cardiogenic shock. AMICS indicates acute myocardial infarction complicated by cardiogenic shock. **** represents P&lt;0.0001.</p>
                  </caption>
                  <graphic xlink:href="JAH3-10-e021570-g001" position="anchor" id="jats-graphic-7"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah36846-sec-0019">
              <title>DISCUSSION</title>
              <p>We sought to evaluate differences in outcomes between AMICS and non‐AMICS in a highly defined population. In this analysis, we identified 2 major findings. First, compared with patients with non‐AMI, individuals presenting with AMI are at higher risk for adverse events. This was largely driven by increased rate of 30‐day all‐cause mortality, need for mechanical circulatory support, and initiation of RRT. Second, urine output was significantly reduced, and contrast administration was higher in patients with AMI likely contributing to increased need for RRT. Importantly, there were no differences in hemodynamic status between AMICS versus non‐AMICS and contrast use may have contributed to differences observed in renal outcomes. Finally, despite concerns about dobutamine increasing heart rate and myocardial oxygen consumption, no differences in clinical outcomes were observed between dobutamine and milrinone. Taken together, these findings suggest important differences in care pathways and outcomes exist between these subgroups of patients with CS.</p>
              <p>In this substudy of the randomized DOREMI trial, we evaluated clinical outcomes stratified by AMICS. Previous trials such as the SHOCK trial have demonstrated the benefit of coronary revascularization in AMICS.<xref rid="jah36846-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah36846-bib-0005" ref-type="bibr"><sup>5</sup></xref> Furthermore, CULPRIT‐SHOCK suggested the superiority of culprit‐only revascularization compared with multivessel disease revascularization at the time of presentation on early outcomes including renal dysfunction.<xref rid="jah36846-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jah36846-bib-0007" ref-type="bibr"><sup>7</sup></xref> Given their focus on revascularization, these trials were necessarily focused on patients with AMICS and comparative data to non‐AMICS remain limited. Moreover, our results are consistent with a registry study showing a similar rate of in‐hospital mortality in AMICS and non‐AMICS.<xref rid="jah36846-bib-0003" ref-type="bibr"><sup>3</sup></xref> Despite contemporary supportive treatment with coronary revascularization improving in‐hospital mortality rates,<xref rid="jah36846-bib-0003" ref-type="bibr"><sup>3</sup></xref> our findings demonstrate high rates of primary composite event in AMICS, highlighting an opportunity to improve outcomes in this patient population.</p>
              <p>The use of dobutamine in AMICS raised concerns because of its effect on heart rate and myocardial oxygen consumption. Dobutamine is a synthetic catecholamine with beta‐1 and beta‐2 receptor agonist activity, whereas milrinone is a phosphodiesterase‐3 inhibitor which affects cardiac inotropy, lusitropy, and peripheral vasodilation. Indeed, the effect of different inotropes on mortality in AMICS remains poorly studied with no definitive evidence to date.<xref rid="jah36846-bib-0016" ref-type="bibr"><sup>16</sup></xref> A substudy of the CardShock trial demonstrated similar outcomes in a combination treatment of norepinephrine with dobutamine or levosimendan.<xref rid="jah36846-bib-0017" ref-type="bibr"><sup>17</sup></xref> Furthermore, although levosimendan compared with dobutamine was associated with short‐term mortality benefits, it conferred no long‐term mortality benefits in long‐term follow‐up.<xref rid="jah36846-bib-0016" ref-type="bibr"><sup>16</sup></xref> Our findings complement previous findings in that no differences in the primary composite end point between dobutamine and milrinone in AMICS was observed.</p>
              <p>We also observed an increased need for RRT at 30 days in patients with AMICS. No differences in baseline characteristics which may predispose the patient to RRT such as baseline renal function, baseline Society for Cardiovascular Angiography and Interventions class, or chronic kidney disease were observed. Furthermore, both groups had a high rate of acute kidney injury with patients with AMICS more likely to require RRT. In our cohort, patients with AMICS received greater contrast volume during angiography. Iodinated contrast are hypothesized to be toxic to tubular epithelial cells and impede renal blood flow through a combination of arteriolar vasoconstriction and increase in blood osmolality and viscosity—both of which may potentially contribute to contrast‐associated acute kidney injury.<xref rid="jah36846-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="jah36846-bib-0019" ref-type="bibr"><sup>19</sup></xref> Furthermore, transition to RRT may be partially explained by patients presenting with ST‐segment elevation myocardial infarction who are at high‐risk of contrast‐associated acute kidney injury.<xref rid="jah36846-bib-0020" ref-type="bibr"><sup>20</sup></xref> Other factors which impact progression to RRT may include athero‐embolic complications.<xref rid="jah36846-bib-0021" ref-type="bibr"><sup>21</sup></xref> Strategies to restrict contrast use during catheterization and revascularization is paramount to attenuate progression to RRT.</p>
              <sec id="jah36846-sec-0020">
                <title>Study Limitations</title>
                <p>Certainly, our study is not without limitations. First, it was limited to in‐hospital outcomes as per the design of the clinical trial. Thus, we are not able to comment on long‐term outcomes between the 2 groups and differences may exist. Second, the findings of increased renal injury and RRT in patients with AMI may be unavoidable owing to the need to revascularize patients with an ischemic trigger. However, both CULPRIT‐SHOCK<xref rid="jah36846-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jah36846-bib-0007" ref-type="bibr"><sup>7</sup></xref> and recent observational findings support minimizing revascularization and contrast exposure at the time of presentation.<xref rid="jah36846-bib-0022" ref-type="bibr"><sup>22</sup></xref> Our data echo these studies highlighting worse renal outcomes compared with those without an ischemic trigger. Third, majority of participants in the DOREMI trial presented with Society for Cardiovascular Angiography and Interventions cardiogenic shock stage C. Fourth, we did not account for the competing risk of death with respect to length of stay between the 2 groups in the cohort. Fifth, the evaluation of secondary outcomes such as transient ischemic attack or stroke were limited by small sample size. Finally, only patients with STEMI presenting with AMI underwent a revascularization procedure immediately—a pattern of practice within the randomization center. More aggressive revascularization of patients with NSTEMI may have further magnified differences between the groups—particularly as it pertains to renal outcomes.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah36846-sec-0021">
              <title>CONCLUSIONS</title>
              <p>AMICS is associated with increased rates of adverse clinical outcomes compared with non‐AMICS. In particular, all‐cause mortality, RRT, and escalation to mechanical circulatory support were more common in patients with AMICS. Moreover, renal protective strategies such as reducing contrast use and limiting revascularization to culprit‐only lesions maybe beneficial in this cohort.</p>
            </sec>
            <sec id="jah36846-sec-0023">
              <title>Sources of Funding</title>
              <p>This project was supported by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario and Canadian Foundation of Innovation. Jung was funded by the Vanier Canadian Institutes of Health Research Canada Graduate Scholarship.</p>
            </sec>
            <sec id="jah36846-sec-0024">
              <title>Disclosures</title>
              <p>Dr Hibbert reports funding as a clinical trial investigator from Abbott, Boston Scientific, and Edwards Lifesciences outside of the submitted work. The remaining authors have no disclosures to report.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jah36846-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Table S1</p>
                  <p>Figures S1–S3</p>
                </caption>
                <media xlink:href="JAH3-10-e021570-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah36846-sec-0022">
              <title>Acknowledgments</title>
              <p>The authors would like to thank all the collaborators and CAPITAL Research Group for all their support and guidance for the completion of the project.</p>
              <p>Author contributions: Jung, Di Santo, Mathew, and Hibbert contributed to the conception/design, and drafted the work for the study. Abdel‐Razek, Parlow, Simard, Marbach, Gillmore, Mao, Bernick, Theriault‐Lauzier, Fu, Lau, Motazedian, Russo, and Labinaz contributed to the acquisition of the data. Jung, Di Santo, Bernick, and Hibbert contributed to the interpretation of the study. All authors approved the submitted version of the manuscript and agree to be accountable for all aspects of the work to be published.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah36846-bibl-0001">
              <title>References</title>
              <ref id="jah36846-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0001"><string-name><surname>van Diepen</surname><given-names>S</given-names></string-name>, <string-name><surname>Katz</surname><given-names>JN</given-names></string-name>, <string-name><surname>Albert</surname><given-names>NM</given-names></string-name>, <string-name><surname>Henry</surname><given-names>TD</given-names></string-name>, <string-name><surname>Jacobs</surname><given-names>AK</given-names></string-name>, <string-name><surname>Kapur</surname><given-names>NK</given-names></string-name>, <string-name><surname>Kilic</surname><given-names>A</given-names></string-name>, <string-name><surname>Menon</surname><given-names>V</given-names></string-name>, <string-name><surname>Ohman</surname><given-names>EM</given-names></string-name>, <string-name><surname>Sweitzer</surname><given-names>NK</given-names></string-name>, et al. <article-title>Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association</article-title>. <source>Circulation</source>. <year>2017</year>;<volume>136</volume>:<fpage>e232</fpage>–<lpage>e268</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000525</pub-id>
<pub-id pub-id-type="pmid">28923988</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0002"><string-name><surname>Thiele</surname><given-names>H</given-names></string-name>, <string-name><surname>Ohman</surname><given-names>EM</given-names></string-name>, <string-name><surname>de Waha‐Thiele</surname><given-names>S</given-names></string-name>, <string-name><surname>Zeymer</surname><given-names>U</given-names></string-name>, <string-name><surname>Desch</surname><given-names>S</given-names></string-name>. <article-title>Management of cardiogenic shock complicating myocardial infarction: an update 2019</article-title>. <source>Eur Heart J</source>. <year>2019</year>;<volume>40</volume>:<fpage>2671</fpage>–<lpage>2683</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehz363</pub-id>
<pub-id pub-id-type="pmid">31274157</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0003"><string-name><surname>Berg</surname><given-names>DD</given-names></string-name>, <string-name><surname>Bohula</surname><given-names>EA</given-names></string-name>, <string-name><surname>Van Diepen</surname><given-names>S</given-names></string-name>, <string-name><surname>Katz</surname><given-names>JN</given-names></string-name>, <string-name><surname>Alviar</surname><given-names>CL</given-names></string-name>, <string-name><surname>Baird‐Zars</surname><given-names>VM</given-names></string-name>, <string-name><surname>Barnett</surname><given-names>CF</given-names></string-name>, <string-name><surname>Barsness</surname><given-names>GW</given-names></string-name>, <string-name><surname>Burke</surname><given-names>JA</given-names></string-name>, <string-name><surname>Cremer</surname><given-names>PC</given-names></string-name>, et al. <article-title>Epidemiology of shock in contemporary cardiac intensive care units</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2019</year>;<volume>12</volume>:<elocation-id>e005618</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.119.005618</pub-id><pub-id pub-id-type="pmid">30879324</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0004"><string-name><surname>Hochman</surname><given-names>JS</given-names></string-name>, <string-name><surname>Sleeper</surname><given-names>LA</given-names></string-name>, <string-name><surname>Webb</surname><given-names>JG</given-names></string-name>, <string-name><surname>Dzavik</surname><given-names>V</given-names></string-name>, <string-name><surname>Buller</surname><given-names>CE</given-names></string-name>, <string-name><surname>Aylward</surname><given-names>P</given-names></string-name>, <string-name><surname>Col</surname><given-names>J</given-names></string-name>, <string-name><surname>White</surname><given-names>HD</given-names></string-name>; <collab collab-type="authors">Investigators S</collab>
. <article-title>Early revascularization and long‐term survival in cardiogenic shock complicating acute myocardial infarction</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>295</volume>:<fpage>2511</fpage>–<lpage>2515</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.295.21.2511</pub-id>
<pub-id pub-id-type="pmid">16757723</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0005"><string-name><surname>Hochman</surname><given-names>JS</given-names></string-name>, <string-name><surname>Sleeper</surname><given-names>LA</given-names></string-name>, <string-name><surname>Webb</surname><given-names>JG</given-names></string-name>, <string-name><surname>Sanborn</surname><given-names>TA</given-names></string-name>, <string-name><surname>White</surname><given-names>HD</given-names></string-name>, <string-name><surname>Talley</surname><given-names>JD</given-names></string-name>, <string-name><surname>Buller</surname><given-names>CE</given-names></string-name>, <string-name><surname>Jacobs</surname><given-names>AK</given-names></string-name>, <string-name><surname>Slater</surname><given-names>JN</given-names></string-name>, <string-name><surname>Col</surname><given-names>J</given-names></string-name>, et al. <article-title>Early revascularization in acute myocardial infarction complicated by cardiogenic shock</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>341</volume>:<fpage>625</fpage>–<lpage>634</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM199908263410901</pub-id>
<pub-id pub-id-type="pmid">10460813</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0006"><string-name><surname>Thiele</surname><given-names>H</given-names></string-name>, <string-name><surname>Akin</surname><given-names>I</given-names></string-name>, <string-name><surname>Sandri</surname><given-names>M</given-names></string-name>, <string-name><surname>de Waha‐Thiele</surname><given-names>S</given-names></string-name>, <string-name><surname>Meyer‐Saraei</surname><given-names>R</given-names></string-name>, <string-name><surname>Fuernau</surname><given-names>G</given-names></string-name>, <string-name><surname>Eitel</surname><given-names>I</given-names></string-name>, <string-name><surname>Nordbeck</surname><given-names>P</given-names></string-name>, <string-name><surname>Geisler</surname><given-names>T</given-names></string-name>, <string-name><surname>Landmesser</surname><given-names>U</given-names></string-name>, et al. <article-title>One‐year outcomes after PCI strategies in cardiogenic shock</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>1699</fpage>–<lpage>1710</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1808788</pub-id>
<pub-id pub-id-type="pmid">30145971</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0007"><string-name><surname>Thiele</surname><given-names>H</given-names></string-name>, <string-name><surname>Akin</surname><given-names>I</given-names></string-name>, <string-name><surname>Sandri</surname><given-names>M</given-names></string-name>, <string-name><surname>Fuernau</surname><given-names>G</given-names></string-name>, <string-name><surname>de Waha</surname><given-names>S</given-names></string-name>, <string-name><surname>Meyer‐Saraei</surname><given-names>R</given-names></string-name>, <string-name><surname>Nordbeck</surname><given-names>P</given-names></string-name>, <string-name><surname>Geisler</surname><given-names>T</given-names></string-name>, <string-name><surname>Landmesser</surname><given-names>U</given-names></string-name>, <string-name><surname>Skurk</surname><given-names>C</given-names></string-name>, et al. <article-title>PCI strategies in patients with acute myocardial infarction and cardiogenic shock</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>:<fpage>2419</fpage>–<lpage>2432</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1710261</pub-id>
<pub-id pub-id-type="pmid">29083953</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0008"><string-name><surname>Alexander</surname><given-names>JH</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>HR</given-names></string-name>, <string-name><surname>Stebbins</surname><given-names>AL</given-names></string-name>, <string-name><surname>Dzavik</surname><given-names>V</given-names></string-name>, <string-name><surname>Harrington</surname><given-names>RA</given-names></string-name>, <string-name><surname>Van de Werf</surname><given-names>F</given-names></string-name>, <string-name><surname>Hochman</surname><given-names>JS</given-names></string-name>. <article-title>Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial</article-title>. <source>JAMA</source>. <year>2007</year>;<volume>297</volume>:<fpage>1657</fpage>–<lpage>1666</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.297.15.joc70035</pub-id>
<pub-id pub-id-type="pmid">17387132</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0009"><string-name><surname>Thiele</surname><given-names>H</given-names></string-name>, <string-name><surname>Zeymer</surname><given-names>U</given-names></string-name>, <string-name><surname>Neumann</surname><given-names>F‐J</given-names></string-name>, <string-name><surname>Ferenc</surname><given-names>M</given-names></string-name>, <string-name><surname>Olbrich</surname><given-names>H‐G</given-names></string-name>, <string-name><surname>Hausleiter</surname><given-names>J</given-names></string-name>, <string-name><surname>Richardt</surname><given-names>G</given-names></string-name>, <string-name><surname>Hennersdorf</surname><given-names>M</given-names></string-name>, <string-name><surname>Empen</surname><given-names>K</given-names></string-name>, <string-name><surname>Fuernau</surname><given-names>G</given-names></string-name>, et al. <article-title>Intraaortic balloon support for myocardial infarction with cardiogenic shock</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>:<fpage>1287</fpage>–<lpage>1296</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1208410</pub-id>
<pub-id pub-id-type="pmid">22920912</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0010"><string-name><surname>Levy</surname><given-names>B</given-names></string-name>, <string-name><surname>Clere‐Jehl</surname><given-names>R</given-names></string-name>, <string-name><surname>Legras</surname><given-names>A</given-names></string-name>, <string-name><surname>Morichau‐Beauchant</surname><given-names>T</given-names></string-name>, <string-name><surname>Leone</surname><given-names>M</given-names></string-name>, <string-name><surname>Frederique</surname><given-names>G</given-names></string-name>, <string-name><surname>Quenot</surname><given-names>J‐P</given-names></string-name>, <string-name><surname>Kimmoun</surname><given-names>A</given-names></string-name>, <string-name><surname>Cariou</surname><given-names>A</given-names></string-name>, <string-name><surname>Lassus</surname><given-names>J</given-names></string-name>, et al. <article-title>Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2018</year>;<volume>72</volume>:<fpage>173</fpage>–<lpage>182</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2018.04.051</pub-id>
<pub-id pub-id-type="pmid">29976291</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0011"><string-name><surname>Fuhrmann</surname><given-names>JT</given-names></string-name>, <string-name><surname>Schmeisser</surname><given-names>A</given-names></string-name>, <string-name><surname>Schulze</surname><given-names>MR</given-names></string-name>, <string-name><surname>Wunderlich</surname><given-names>C</given-names></string-name>, <string-name><surname>Schoen</surname><given-names>SP</given-names></string-name>, <string-name><surname>Rauwolf</surname><given-names>T</given-names></string-name>, <string-name><surname>Weinbrenner</surname><given-names>C</given-names></string-name>, <string-name><surname>Strasser</surname><given-names>RH</given-names></string-name>. <article-title>Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction*</article-title>. <source>Crit Care Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>2257</fpage>–<lpage>2266</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CCM.0b013e3181809846</pub-id>
<pub-id pub-id-type="pmid">18664782</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0012"><string-name><surname>Mathew</surname><given-names>R</given-names></string-name>, <string-name><surname>Di Santo</surname><given-names>P</given-names></string-name>, <string-name><surname>Jung</surname><given-names>RG</given-names></string-name>, <string-name><surname>Marbach</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hutson</surname><given-names>J</given-names></string-name>, <string-name><surname>Simard</surname><given-names>T</given-names></string-name>, <string-name><surname>Ramirez</surname><given-names>FD</given-names></string-name>, <string-name><surname>Harnett</surname><given-names>DT</given-names></string-name>, <string-name><surname>Merdad</surname><given-names>A</given-names></string-name>, <string-name><surname>Almufleh</surname><given-names>A</given-names></string-name>, et al. <article-title>Milrinone as compared with dobutamine in the treatment of cardiogenic shock</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>:<fpage>516</fpage>–<lpage>525</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2026845</pub-id>
<pub-id pub-id-type="pmid">34347952</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0013"><string-name><surname>Baran</surname><given-names>DA</given-names></string-name>, <string-name><surname>Grines</surname><given-names>CL</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>S</given-names></string-name>, <string-name><surname>Burkhoff</surname><given-names>D</given-names></string-name>, <string-name><surname>Hall</surname><given-names>SA</given-names></string-name>, <string-name><surname>Henry</surname><given-names>TD</given-names></string-name>, <string-name><surname>Hollenberg</surname><given-names>SM</given-names></string-name>, <string-name><surname>Kapur</surname><given-names>NK</given-names></string-name>, <string-name><surname>O'Neill</surname><given-names>W</given-names></string-name>, <string-name><surname>Ornato</surname><given-names>JP</given-names></string-name>, et al. <article-title>SCAI clinical expert consensus statement on the classification of cardiogenic shock</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2019</year>;<volume>94</volume>:<fpage>29</fpage>–<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ccd.28329</pub-id>
<pub-id pub-id-type="pmid">31104355</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0014"><string-name><surname>Thygesen</surname><given-names>K</given-names></string-name>, <string-name><surname>Alpert Joseph</surname><given-names>S</given-names></string-name>, <string-name><surname>Jaffe Allan</surname><given-names>S</given-names></string-name>, <string-name><surname>Simoons Maarten</surname><given-names>L</given-names></string-name>, <string-name><surname>Chaitman Bernard</surname><given-names>R</given-names></string-name>, <string-name><surname>White</surname><given-names>HD</given-names></string-name>. <article-title>Third universal definition of myocardial infarction</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>126</volume>:<fpage>2020</fpage>–<lpage>2035</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIR.0b013e31826e1058</pub-id>
<pub-id pub-id-type="pmid">22923432</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0015"><string-name><surname>Na</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Chung</surname><given-names>CR</given-names></string-name>, <string-name><surname>Cho</surname><given-names>YH</given-names></string-name>, <string-name><surname>Jeon</surname><given-names>K</given-names></string-name>, <string-name><surname>Suh</surname><given-names>GY</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>JH</given-names></string-name>, <string-name><surname>Carriere</surname><given-names>KC</given-names></string-name>, <string-name><surname>Park</surname><given-names>TK</given-names></string-name>, <string-name><surname>Lee</surname><given-names>GY</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JM</given-names></string-name>, et al. <article-title>Vasoactive inotropic score as a predictor of mortality in adult patients with cardiogenic shock: medical therapy versus ECMO</article-title>. <source>Rev Esp Cardiol (Engl Ed)</source>. <year>2019</year>;<volume>72</volume>:<fpage>40</fpage>–<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.rec.2018.01.003</pub-id>
<pub-id pub-id-type="pmid">29463462</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0016"><string-name><surname>Schumann</surname><given-names>J</given-names></string-name>, <string-name><surname>Henrich</surname><given-names>EC</given-names></string-name>, <string-name><surname>Strobl</surname><given-names>H</given-names></string-name>, <string-name><surname>Prondzinsky</surname><given-names>R</given-names></string-name>, <string-name><surname>Weiche</surname><given-names>S</given-names></string-name>, <string-name><surname>Thiele</surname><given-names>H</given-names></string-name>, <string-name><surname>Werdan</surname><given-names>K</given-names></string-name>, <string-name><surname>Frantz</surname><given-names>S</given-names></string-name>, <string-name><surname>Unverzagt</surname><given-names>S</given-names></string-name>. <article-title>Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>1</volume>:<fpage>CD009669</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD009669.pub3</pub-id><pub-id pub-id-type="pmid">29376560</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0017"><string-name><surname>Tarvasmäki</surname><given-names>T</given-names></string-name>, <string-name><surname>Lassus</surname><given-names>J</given-names></string-name>, <string-name><surname>Varpula</surname><given-names>M</given-names></string-name>, <string-name><surname>Sionis</surname><given-names>A</given-names></string-name>, <string-name><surname>Sund</surname><given-names>R</given-names></string-name>, <string-name><surname>Køber</surname><given-names>L</given-names></string-name>, <string-name><surname>Spinar</surname><given-names>J</given-names></string-name>, <string-name><surname>Parissis</surname><given-names>J</given-names></string-name>, <string-name><surname>Banaszewski</surname><given-names>M</given-names></string-name>, <string-name><surname>Silva Cardoso</surname><given-names>J</given-names></string-name>, et al. <article-title>Current real‐life use of vasopressors and inotropes in cardiogenic shock—adrenaline use is associated with excess organ injury and mortality</article-title>. <source>Crit Care</source>. <year>2016</year>;<volume>20</volume>:<fpage>208</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13054-016-1387-1</pub-id><pub-id pub-id-type="pmid">27374027</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0018"><string-name><surname>Almendarez</surname><given-names>M</given-names></string-name>, <string-name><surname>Gurm</surname><given-names>HS</given-names></string-name>, <string-name><surname>Mariani</surname><given-names>J</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Montorfano</surname><given-names>M</given-names></string-name>, <string-name><surname>Brilakis</surname><given-names>ES</given-names></string-name>, <string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Azzalini</surname><given-names>L</given-names></string-name>. <article-title>Procedural strategies to reduce the incidence of contrast‐induced acute kidney injury during percutaneous coronary intervention</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2019</year>;<volume>12</volume>:<fpage>1877</fpage>–<lpage>1888</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2019.04.055</pub-id>
<pub-id pub-id-type="pmid">31521648</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0019"><string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Dangas</surname><given-names>GD</given-names></string-name>, <string-name><surname>Weisbord</surname><given-names>SD</given-names></string-name>. <article-title>Contrast‐associated acute kidney injury</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>:<fpage>2146</fpage>–<lpage>2155</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMra1805256</pub-id>
<pub-id pub-id-type="pmid">31141635</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0020"><string-name><surname>Sgura</surname><given-names>FA</given-names></string-name>, <string-name><surname>Bertelli</surname><given-names>L</given-names></string-name>, <string-name><surname>Monopoli</surname><given-names>D</given-names></string-name>, <string-name><surname>Leuzzi</surname><given-names>C</given-names></string-name>, <string-name><surname>Guerri</surname><given-names>E</given-names></string-name>, <string-name><surname>Spartà</surname><given-names>I</given-names></string-name>, <string-name><surname>Politi</surname><given-names>L</given-names></string-name>, <string-name><surname>Aprile</surname><given-names>A</given-names></string-name>, <string-name><surname>Amato</surname><given-names>A</given-names></string-name>, <string-name><surname>Rossi</surname><given-names>R</given-names></string-name>, et al. <article-title>Mehran contrast‐induced nephropathy risk score predicts short‐ and long‐term clinical outcomes in patients with ST‐elevation–myocardial infarction</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>:<fpage>491</fpage>–<lpage>498</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.110.955310</pub-id>
<pub-id pub-id-type="pmid">20923986</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0021"><string-name><surname>Ando</surname><given-names>G</given-names></string-name>, <string-name><surname>Costa</surname><given-names>F</given-names></string-name>, <string-name><surname>Trio</surname><given-names>O</given-names></string-name>, <string-name><surname>Oreto</surname><given-names>G</given-names></string-name>, <string-name><surname>Valgimigli</surname><given-names>M</given-names></string-name>. <article-title>Impact of vascular access on acute kidney injury after percutaneous coronary intervention</article-title>. <source>Cardiovasc Revasc Med</source>. <year>2016</year>;<volume>17</volume>:<fpage>333</fpage>–<lpage>338</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.carrev.2016.03.004</pub-id>
<pub-id pub-id-type="pmid">27050627</pub-id></mixed-citation>
              </ref>
              <ref id="jah36846-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah36846-cit-0022"><string-name><surname>Khera</surname><given-names>R</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Desai</surname><given-names>NR</given-names></string-name>, <string-name><surname>Krumholz</surname><given-names>HM</given-names></string-name>, <string-name><surname>Maddox</surname><given-names>TM</given-names></string-name>, <string-name><surname>Shunk</surname><given-names>KA</given-names></string-name>, <string-name><surname>Virani</surname><given-names>SS</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>J</given-names></string-name>, et al. <article-title>Revascularization practices and outcomes in patients with multivessel coronary artery disease who presented with acute myocardial infarction and cardiogenic shock in the US, 2009–2018</article-title>. <source>JAMA Intern Med</source>. <year>2020</year>;<volume>180</volume>:<fpage>1317</fpage>–<lpage>1327</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.3276</pub-id>
<pub-id pub-id-type="pmid">32833024</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
